|Table of Contents|

Efficacy and influencing factors of neoadjuvant chemotherapy in 167 cases with stage Ⅱ,Ⅲ breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

2015 13
Research Field:
Publishing date:


Efficacy and influencing factors of neoadjuvant chemotherapy in 167 cases with stage Ⅱ,Ⅲ breast cancer
Zhang Xiaofei1Qin Qinghong1Lian Bin1Yu Yinghua1Huang Zhen1Yang Weiping2Wei Changyuan1Mo Qinguo1
1.Department of Breast Surgery,The Affiliated Tumor Hospital of Guangxi Medical University,Guangxi Nanning 530021,China;2.Ultrasonic Department,The Affiliated Tumor Hospital of Guangxi Medical University,Guangxi Nanning 530021,China.
breast cancerneoaduvant chemotherapyefficacyinfluencing factor
Objective:To investigate the efficacy and influencing factors of neoadjuvant chemotherapy in breast cancer.Methods:All 167 cases with operable stage Ⅱ,Ⅲ breast cancer were treated with anthracycline or paclitaxel class-based neoadjuvant chemotherapy,the efficacy was evaluated by MRI imaging methods.Factors affecting the effect of chemotherapy was determinated by univariate analysis and multivariate Logistic regression analysis.Results:In the 167 breast cancer patients,complete remission (CR) was obsered in 24 cases (14.4%),pathological complete response (pCR) 20 cases (12%),partial remission (PR) 90 cases (53.9%),stable disease (SD) 43 cases (25.7%),progressive disease (PD) 10 cases (6%).The overall effective rate was 68.3%.Univariate analysis showed that:Influence facters,such as tumor size,calcification,ER and PR status,chemotherapy cycles and chemotherapy regimens,on neoadjuvant chemotherapy for breast cancer was statistically significant (P<0.05).In patients whose tumor diameter ≤3cm,mammography no calcification,ER or PR negative,the number of chemotherapy cycles≥4,Anthracycline plus Xeloda regimen,the efficacy of neoadjuvant chemotherapy was better,CR rate was higher.Multivariate analysis showed that:Tumor size was an independent predictive factor for CR rate to neoadjuvant chemotherapy.With the increase in tumor size,CR rate gradually decreased.Conclusion:The neoaduvant chemotherapy for breast cancer have a good recent effect,but its efficacy is impacted by various factors,such as tumor size,calcification,ER and PR status,chemotherapy cycles and chemotherapy regimens.


[1]Spanheimer PM,Carr JC,Thomas A,et al.The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer[J].Am J Surg,2013,206(1):2-7.
[2]Yu Y,Xiang H,He XM,et al.Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer-a single center experience[J].Asian Pac J Cancer Prev,2013,14(4):2401-2406.
[3]Zhou LY,Shi YH,Wang X,et al.Efficacy of neoadjuvant chemotherapy in patients with triple-negative breast cancer and prognostic analysis[J].Tumor,2014,34(5):454-457.[周立艳,史业辉,汪旭,等.三阴性乳腺癌新辅助化疗疗效及预后分析[J].肿瘤,2014,34(5):454-457.]
[4]Kawajiri H,Takashima T,Aomatsu N,et al.Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer[J].Oncol Lett,2014,7(3):663-668.
[5]Hammond ME,Hayes DF,Dowsett M,et al.American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].Arch Pathol Lab Med,2010,134(6):907-922.
[6]Hu XC,Wang BY,Shao ZM.The comparison of 《St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011》 and guidelines for chinese anti-cancer association,committee of breast cancer society[J].Chin J Breast Dis(Electronic Version),2011,5(4):404-407.[胡夕春,王碧芸,邵志敏.2011年《St.Gallen早期乳腺癌初治治疗国际专家共识》与中国抗癌协会乳腺癌专业委员会指南之比较[J].中华乳腺病杂志(电子版),2011,5(4):404-407.]
[7]Sun B,Song ST,Jiang ZF,et al.Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breastcancer patients[J].Chin J Oncol,2013,35(1):38-42.[孙冰,宋三泰,江泽飞,等.乳腺癌新辅助化疗病理完全缓解的影响因素分析[J].中华肿瘤杂志,2013,35(1):38-42.]
[8]Straver ME,Van Adrichem JC,Rutgers EJ,et al.Neoadjuvant systemictherapy in patients with operable primary breast cancer:more benefits than breast-conserving therapy[J].Ned Tijdschr Geneeskd,2008,152(46):2519-2525.
[9]Gao DZ,Fu QY,Zhang Q,et al.The effect of 6 cycles ET neoadjuvant chemotherapy regimen on breast cancer and its influencing factors[J].Chin J General Surg,2012,27(5):398-401.[高德宗,傅勤烨,张强,等.乳腺癌6周期ET方案新辅助化疗的疗效及其影响因素分析[J].中华普通外科杂志,2012,27(5):398-401.]
[10]Weiss A,Lee KC,Romero Y,et al.Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy[J].Ann Surg Oncol,2014,21(10):3310-3316.
[11]Zhang HT,Zhao YB,Song PJ,et al.Application of molybdenum target mammography to evaluation of neoadjuvant chemotherapy in breast cancer[J].Military Medical Sciences,2012,36(8):616-618.[张洪涛,赵一冰,宋培记,等.钼靶乳腺摄像在乳腺癌新辅助化疗疗效评价中的应用[J].军事医学,2012,36(8):616-618.]
[12]Jiang L,Ma T,Moran MS,et al.Mammographic features are associated with clinicopathological characteristics in invasive breast cancer[J].Anticancer Res,2011,31(6):2327-2334.
[13]Holmberg L,Wong YN,Tabár L,et al.Mammography casting-type calcification and risk of local recurrence in DCIS:analyses from a randomised study[J].Br J Cancer,2013,108(4):812-819.
[14]Krishnan Y,Alawadhi SA,P SS,et al.Pathological responses and long-term outcome analysis after neoadjuvant chemotheraphy in breast cancer patients from Kuwait over a period of 15 years[J].Ann Saudi Med,2013,33(5):443-450.
[15]Han S,Kim J,Lee J,et al.Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer[J].Eur J Surg Oncol,2009,35(6):583-587.


Last Update: 2015-05-29